Jean‐Jacques Kiladjian

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al. · Blood · 2022 · 2.4K citations · Full text

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin

Nicole Casadevall, J Nataf, B Viron et al. · New England Journal of Medicine · 2002 · 1.2K citations

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer et al. · New England Journal of Medicine · 2015 · 851 citations

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Tiziano Barbui, Giovanni Barosi, Gunnar Birgegård et al. · Journal of Clinical Oncology · 2011 · 825 citations · Full text

Mixed-phenotype Acute Leukemia, European Leukemianet, Pathology +16